Telesis Bio (TBIO) Short Interest Ratio & Short Volume

Short interest is the volume of Telesis Bio shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 29,700 shares of TBIO short. 5.67% of Telesis Bio's shares are currently sold short. Learn More on Telesis Bio's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.67% of Telesis Bio's floating shares are currently sold short.

Telesis Bio saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 29,700 shares, an increase of 141.5% from the previous total of 12,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Telesis Bio currently has issued a total of 1,773,000 shares. Some of Telesis Bio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Telesis Bio currently has a public float of 524,000 shares.

5.67% of Telesis Bio's shares are currently sold short. Here is how the short interest of companies compare to Telesis Bio: Precipio, Inc. (0.38%), Talis Biomedical Co. (1.20%), Spectaire Holdings Inc. (3.50%), ThermoGenesis Holdings, Inc. (1.94%), Coherus BioSciences, Inc. (25.91%), Compugen Ltd. (1.74%), Black Diamond Therapeutics, Inc. (12.95%), Adverum Biotechnologies, Inc. (12.04%), C4 Therapeutics, Inc. (9.59%), Sangamo Therapeutics, Inc. (8.75%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($6.15 billion), Charter Communications, Inc. ($4.04 billion), Paychex, Inc. ($2.77 billion), Nu Holdings Ltd. ($2.71 billion), Cencora, Inc. ($2.34 billion), Aptiv PLC ($2.18 billion), Tractor Supply ($2.07 billion), International Paper ($2.01 billion), AppLovin Co. ($1.95 billion), and Moderna, Inc. ($1.89 billion). View all of the most shorted stocks.

Short selling TBIO is an investing strategy that aims to generate trading profit from Telesis Bio as its price is falling. TBIO shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Telesis Bio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TBIO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TBIO, twice per month. The most recent reporting period available is September, 15 2024.